Upstream Bio: Hold Rating As Verekitug Faces Competition Among Latest Asthma Data [Seeking Alpha]
Upstream Bio, Inc. (UPB)
Company Research
Source: Seeking Alpha
Verekitug achieved a 56% AAER reduction at 100 mg Q12W and 39% at 400 mg Q24W, offering competitive dosing versus Tezspire. Competitive threats loom as multiple companies pursue long-acting anti-TSLP antibodies with potentially superior efficacy and less frequent dosing. UPB remains well-capitalized through 2027, but future value hinges on rival data and regulatory outcomes for phase 3 advancement. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » valentinrussanov/E+ via Getty Images The last time I spoke about Upstream Bio, Inc. ( UPB ), it was in a Seeking Alpha article entitled " Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to
Show less
Read more
Impact Snapshot
Event Time:
UPB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UPB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UPB alerts
High impacting Upstream Bio, Inc. news events
Weekly update
A roundup of the hottest topics
UPB
News
- Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe AsthmaGlobeNewswire
- Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma [Yahoo! Finance]Yahoo! Finance
- Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe AsthmaGlobeNewswire
- Upstream Bio: Fully Priced After Recent Rally [Seeking Alpha]Seeking Alpha
- Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
UPB
Sec Filings
- 2/11/26 - Form 8-K
- 2/11/26 - Form 8-K
- 1/6/26 - Form 4
- UPB's page on the SEC website